2016/17流感季北京门诊流感疫苗效果:检测阴性病例对照研究
研究评估2016/17流感季北京门诊流感疫苗效果,纳入10496例流感样病例,采用检测阴性病例对照设计。调整后对所有流感疫苗效果低,为25%(95%CI:0-43%);对甲型H1N1pdm09为54%(95%CI:22-73%),对甲型H3N2为2%(95%CI:-35%至29%)。
要点
- 2016/17流感季北京门诊流感疫苗效果对所有流感低,为25%(95%CI:0-43%)。
- 对甲型H1N1pdm09疫苗效果中等,为54%(95%CI:22-73%)。
- 对甲型H3N2疫苗效果低,为2%(95%CI:-35%至29%)。
核心结论
- 研究提示2016/17流感季北京门诊对甲型H1N1pdm09疫苗效果中等,但对甲型H3N2疫苗效果低。
- 血凝素氨基酸替换可能贡献于该季对甲型H3N2的低疫苗效果。
研究设计与样本
- 基于监测的研究纳入2016年11月至2017年4月所有经流感病毒学监测的拭子患者。
- 采用检测阴性病例对照设计估计门诊就医且实验室确诊流感的疫苗效果。
- 病例为流感样病例(ILI)中流感检测阳性患者,对照为流感阴性患者。
主要发现
- 共纳入并拭子采样10496例ILI患者。
- 其中735例检测为甲型H1N1pdm09阳性,1851例为甲型H3N2阳性,40例为乙型流感阳性。
- 从1851份甲型H3N2病毒中随机选取45份标本,2份(4.4%)属于H3N2 3C.2a1分支,43份(95.6%)属于A/Hong Kong/4801/2014样3C.2a分支。
- 43份3C.2a分支病毒中,32份病毒聚集于一个携带T131K、R142K和R261Q替换的亚组。
- 调整后对所有流感疫苗效果低,为25%(95%CI:0-43%);对甲型H1N1pdm09为54%(95%CI:22-73%);对甲型H3N2为2%(95%CI:-35%至29%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this study was to estimate influenza vaccine effectiveness (VE) for the 2016/17 epidemic of co-circulating influenza A(H1N1)pdm09 and A(H3N2) viruses in Beijing, the capital of China. METHODS: The surveillance-based study included all swabbed patients through influenza virological surveillance, between November 2016 and April 2017. A test-negative case-control design was used to estimate influenza VE against medically-attended laboratory-confirmed influenza in outpatient settings. Cases were influenza-like illness (ILI) patients who tested positive for influenza, and controls were influenza negative patients. RESULTS: A total of 10,496 ILI patients were enrolled and swabbed. Among them, 735 tested positive for influenza A(H1N1)pdm09, 1851 for A(H3N2), and 40 for type B. Of the 45 randomly selected specimens out of 1851 influenza A(H3N2) viruses, 2(4.4%) belonged to the H3N2 3C.2a1 clade, and 43(95.6%) belonged to A/Hong Kong/4801/2014-like 3C.2a clade. Among the 43 viruses of the 3C.2a clade, 32 viruses clustered in one subgroup carrying T131K, R142K and R261Q substitutions. The adjusted VE against all influenza was low at 25% (95% confidence interval (CI): 0-43%), with 54% (95%CI: 22-73%) for influenza A(H1N1)pdm09, and 2% (95%CI: -35% to 29%) for influenza A(H3N2). CONCLUSIONS: Our study suggested a moderate VE against influenza A(H1N1)pdm09, but low VE against influenza A(H3N2) in Beijing, 2016/17 season. Amino acid substitutions in the hemagglutinin may contribute to the low VE against influenza A(H3N2) for this season.
引用
- Wu S, Pan Y, Zhang X, et al. Influenza vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings: A test-negative case-control study in Beijing, China, 2016/17 season. Vaccine. 2018. PMID: 30087046. doi:10.1016/j.vaccine.2018.07.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。